Substantial injury can occur during reoxygenation of previously ischemic tissue in many experimental models, as the result of the generation of oxygen-derived free radicals. To test the antiradical activity of potentially protective compounds in this setting, we developed a simple screening system, applicable to fresh biopsy specimens, in which warm ischemia and reoxygenation of excised tissue are performed in vitro. Tissue production of malondialdehyde (MDA) equivalents is used as a nonspecific-but-sensitive marker of oxygen radical damage. Test compounds with putative antiradical activity are added prior to the reoxygenation phase, and their ability to suppress MDA production is an index of activity in preventing reoxygenation injury. Comparison with ischemic but not reoxygenated controls confirms the oxygen-dependent nature of the effect. Standard positive controls of known effective agents, such as butylated hydroxytoluene or deferoxamine, provide a reference for the activity of the test compound. The method is applicable to surgical biopsy specimens in veterinary and human medicine.


This is the author accepted manuscript of Salaris, S.C., Babbs, C.F., A rapid, widely applicable screen for drugs that suppress free radical formation in ischemia/reperfusion, Journal of Pharmacological Methods 20, 335-346, 1988. Copyright Elsevier, it is made available here CC-BY-NC-ND, and the version of record is available through the publisher https://doi.org/10.1016/0160-5402(88)90057-5.


Superoxide radical; Hydroxyl radical; Oxygen toxicity; Reperfusion; Reoxygenation; Reperfusion injury; Antioxidant; Iron chelator; Thiobarbituric acid; Malondialdehyde

Date of this Version